Skip to main content
. Author manuscript; available in PMC: 2013 Oct 1.
Published in final edited form as: Am J Transplant. 2012 Jun 13;12(10):2730–2743. doi: 10.1111/j.1600-6143.2012.04144.x

Figure 2. Cumulative incidence of acute and chronic histological lesions by time after transplantation.

Figure 2

Figure 2

(A) Cumulative incidence of clinical (in biopsies for cause) acute T-cell mediated rejection or borderline changes according to treatment arm.

(B) Cumulative incidence of different grades of interstitial fibrosis/tubular atrophy (IFTA), vascular intimal thickening and global glomerulosclerosis by time after transplantation, expressed as 1-the Kaplan-Meier survival estimate.

(C) Cumulative incidence of different grades of interstitial fibrosis/tubular atrophy (IFTA) according to treatment arm. IFTA grade 1 is IFTA encompassing <25% of the biopsy core, while grade 2 corresponds to 25-50% and grade 3 to IFTA in >50% of the biopsy.

For the Kaplan–Meier estimates of event rates presented here, patients were censored at the time of their last biopsy or at 24 months if indication biopsies were performed later than 24 months. The histological lesions were scored according to the updated Banff classification on sequential biopsy specimens obtained on indication (graft dysfunction) and at prescheduled time points (protocol biopsies). P-values comparing survival distribution between SF and SB study group were obtained using the log-rank test.